ICLR vs IQV vs NTRB Stock Comparison

Icon, Iqvia Holdings and NutriBand Prices as of Oct 27, 2026 Peers: Industry group
ICLR Icon Plc
$182.98 +6.2% 1M +0.5% 1Y
Market cap
$16.37B
P/E
36.5x
Revenue (TTM)
$8.23B
Div. yield
–
Contract Research Healthcare
1 win
IQV Iqvia Holdings Inc.
$271.68 +0.7% 1M +25.0% 1Y
Market cap
$45.93B
P/E
33.0x
Revenue (TTM)
$17.31B
Div. yield
–
Contract Research Healthcare
7 wins
NTRB NutriBand Inc.
$5.95 -25.6% 1M -15.4% 1Y
Market cap
$77.80M
P/E
–
Revenue (TTM)
$1.62M
Div. yield
–
Generic Drugs Healthcare
3 wins

Head to Head

11 decided of 12

Iqvia Holdings leads on 7 of the 12 questions below (Iqvia Holdings 7, NutriBand 3, Icon 1). Which ones matter depends on what you are buying for; a cheap multiple and slow growth often come together.

QuestionICLRIQVNTRBLeader
Larger companyMarket capitalisation $16.37B $45.93B $77.80M IQV
Cheaper on earningsLower P/E, profitable companies only 36.5x 33.0x -11.2x IQV
Cheaper on forward earningsLower price / next fiscal year consensus EPS 17.9x 22.4x 3.6x NTRB
Faster revenue growthRevenue growth, trailing twelve months +1.8% +8.8% -37.3% IQV
More profitableNet margin, trailing twelve months 5.4% 8.1% -430.4% IQV
Better return on capitalReturn on invested capital 4.7% 8.2% — IQV
Less leveragedLower net debt / EBITDA 2.3x 3.9x 0.5x NTRB
Higher dividend yieldTrailing dividend yield 0.00% 0.00% 0.00% –
Better 1-year returnPrice return, last 12 months +0.5% +25.0% -15.4% IQV
Better 5-year returnAnnualised price return, 5 years -8.6%/yr +1.1%/yr +2.7%/yr NTRB
Less volatileAnnualised volatility, 1 year 73.7% 40.3% 80.0% IQV
Higher overall scoreMean of the five percentile scores vs peers 81/100 71/100 50/100 ICLR

Percentile Scorecard

ICLRIQVNTRB

Each axis is the mean percentile of its metrics against the company's industry group. 100 is the best in the group, 50 the middle.

Scores by Axis

AxisICLRIQVNTRB
Valuation 100 #1 of 11 80 #3 of 11 53 #295 of 625
Growth 70 #4 of 11 80 #3 of 11 43 #345 of 602
Profitability 80 #3 of 11 90 #2 of 11 36 #356 of 551
Financial Health 75 #4 of 13 33 #9 of 13 68 #210 of 656
Shareholder Returns – – –
Overall 81 71 50
  • ICLR ranked among 13 companies in Pharma Services
  • IQV ranked among 13 companies in Pharma Services
  • NTRB ranked among 672 companies in Pharmaceuticals and Biotechnology

Price Performance

Price return, split-adjusted, before dividends. Click a name to hide or show it.

Returns

PeriodICLRIQVNTRBSPY
1 month +6.2%+0.7%-25.6% -0.2%
3 months +1.5%+11.7%+101.7% +3.9%
6 months +78.5%+70.9%+58.2% +8.2%
Year to date +0.4%+20.5%+31.1% +12.9%
1 year +0.5%+25.0%-15.4% +12.3%
3 years -22.2%+51.0%+182.0% +87.4%
3 years, per year -8.0%+14.7%+41.3% +23.3%
5 years -36.1%+5.6%+14.2% +67.9%
5 years, per year -8.6%+1.1%+2.7% +10.9%
10 years +127.4%+276.8%— +261.1%
10 years, per year +8.6%+14.2%— +13.7%

Risk

MeasureICLRIQVNTRBSPY
Volatility, 1Y 73.7%40.3%80.0% 12.7%
Downside volatility, 1Y 87.6%39.2%75.3% 12.7%
Beta vs S&P 500, 1Y 1.440.741.03 1.00
Return / volatility, 1Y 0.010.62-0.19 0.97
Max drawdown, 5Y -76.9%-51.5%-77.7% -25.4%
From 52-week high -9.8%-2.8%-33.8% -1.2%
52-week high $202.92$279.38$8.99 $779.14
52-week low $80.08$156.66$2.81 $631.97

Valuation History

Weekly multiples on trailing twelve-month fundamentals. Negative or extreme readings (a loss year, a collapsed denominator) are left out so the chart stays readable.

MultipleICLRIQVNTRB
P/E now vs peer median 32.0xmedian 32.1x 32.1xmedian 32.1x -10.4xmedian 17.2x
P/S now vs peer median 1.7xmedian 2.6x 2.6xmedian 2.6x 44.7xmedian 9.0x
EV/EBITDA now vs peer median 15.2xmedian 38.1x 16.9xmedian 38.1x -10.0xmedian 16.3x
P/FCF now vs peer median 16.3xmedian 21.5x 21.5xmedian 21.5x -19.9xmedian 18.7x
P/B now vs peer median 1.5xmedian 3.1x 6.6xmedian 3.1x 13.6xmedian 2.2x
PEG now vs peer median -13.47median 2.03 2.78median 2.03 -12.65median 0.33

Financial History

Reported figures by fiscal period, placed on the calendar year (or quarter) each period ended in, so companies with different fiscal years line up.

Trailing twelve monthsICLRIQVNTRB
Revenue $8.23B $17.31B $1.62M
Gross profit $1.93B $5.72B $536.12K
Operating income $718.25M $2.22B -$7.05M
Net income $448.66M $1.40B -$6.96M
Free cash flow $857.06M $2.08B -$3.63M
R&D – – $1.21M
EPS (diluted) $5.68 $8.35 $-0.57
Cash & equivalents $808.98M $2.25B $3.42M
Total debt $3.38B $16.07B $647.66K
Shares (diluted) 78.97M 167.00M 12.16M
Enterprise value $13.14B $37.19B $60.48M

All Metrics

58 metrics · best in bold

Bold marks the best reading: the lowest positive value for multiples, leverage and payout, the highest for everything else. The bar under each value is its percentile against that company's own peers. Hover a value for its rank and the peer median.

Valuation

12 metrics
MetricICLRIQVNTRB
P/E 32.0x 32.1x -10.4x
P/FCF 16.3x 21.5x -19.9x
P/Operating cash flow 13.6x 16.4x -19.9x
P/S 1.7x 2.6x 44.7x
P/B 1.5x 6.6x 13.6x
P/Tangible book 2.3x 21.8x 14.0x
EV/EBITDA 15.2x 16.9x -10.0x
EV/EBIT 23.1x 26.3x -9.8x
EV/Revenue 2.0x 3.4x 42.7x
EV/FCF 19.3x 28.1x -19.0x
EV/Operating cash flow 16.1x 21.4x -19.0x
PEG (3Y EPS CAGR) -13.47 2.78 -12.65

Growth

14 metrics
MetricICLRIQVNTRB
Revenue growth (1Y) 1.8% 8.8% -37.3%
Revenue CAGR (3Y) 0.9% 5.2% -10.8%
Gross profit growth (1Y) -13.4% 6.6% -39.5%
Gross profit CAGR (3Y) -6.5% 3.4% -16.5%
Operating income growth (1Y) 53.9% 1.7% 32.3%
Operating income CAGR (3Y) -7.0% 6.2% -15.3%
Net income growth (1Y) 55.9% 9.0% 32.2%
Net income CAGR (3Y) -4.4% 7.8% -14.8%
EPS growth (1Y) 30.1% 11.7% 80.0%
EPS CAGR (3Y) -2.4% 11.5% 0.8%
Operating cash flow growth (1Y) -9.9% -2.4% 25.9%
Operating cash flow CAGR (3Y) 15.8% 11.7% -5.7%
Free cash flow growth (1Y) -11.1% -6.0% 26.6%
Free cash flow CAGR (3Y) 18.4% 16.3% -5.5%

Profitability

14 metrics
MetricICLRIQVNTRB
Gross margin 23.4% 33.1% 33.1%
EBITDA margin 13.3% 20.0% -426.5%
Operating margin 8.7% 12.8% -435.6%
Pretax margin 6.3% 9.0% -430.4%
Net margin 5.4% 8.1% -430.4%
FCF margin 10.4% 12.0% -224.5%
Operating cash flow margin 12.5% 15.8% -224.5%
Return on equity 7.6% 21.4% -123.0%
Return on assets 4.3% 4.6% -105.6%
Return on invested capital 4.7% 8.2% –
Return on capital employed 5.3% 9.9% -123.9%
Asset turnover 0.5x 0.6x 0.2x
Cash conversion (OCF / net income) 2.3x 2.0x 0.5x
Stock comp / revenue 1.1% 1.8% 204.1%

Financial Health

11 metrics
MetricICLRIQVNTRB
Debt / assets 20.8% 52.7% 2.4%
Debt / equity 0.4x 2.4x 0.0x
Net debt / EBITDA 2.3x 3.9x 0.5x
Debt / FCF 3.9x 7.7x 0.0x
Liabilities / assets 43.8% 77.7% 15.3%
Equity / assets 56.2% 22.3% 84.7%
Interest coverage 3.4x 2.8x -339.3x
Current ratio 1.3x 0.8x 4.2x
Quick ratio 0.9x 1.0x 3.8x
Cash ratio 0.3x 0.3x 3.8x
Altman Z-score 2.07 2.27 31.26

Shareholder Returns

7 metrics
MetricICLRIQVNTRB
Dividend yield – – –
Net buyback yield 2.7% 2.6% –
Shareholder yield 2.7% 2.6% –
Payout ratio (earnings) – – –
Payout ratio (FCF) – – –
Dividend growth (1Y) – – –
Dividend CAGR (3Y) – – –

Analyst Estimates

Solid lines are reported fiscal-year results; dashed lines are the consensus for the years ahead. Hover a year for the analysts' high and low, and how each result compared with its estimate.

ConsensusICLRIQVNTRB
Forward P/E 17.9xFY2026 22.4xFY2026 3.6xFY2026
EPS, next fiscal year $10.25FY2026 $12.14FY2026 $1.65FY2026
EPS growth, next FY -18.2%FY2026 +1.8%FY2026 –
EPS growth, the year after +22.2% +13.3% +112.1%
Revenue, next fiscal year $8.52BFY2026 $18.58BFY2026 $90.32MFY2026
Revenue growth, next FY +3.2%FY2026 +13.9%FY2026 +4,334.5%FY2026
Revenue growth, the year after -3.2% -3.5% +109.8%

Institutional Ownership

13F filings, quarter ended Jun 30, 2026
HoldersICLRIQVNTRB
Held by institutions 100.0% 94.1% –
Institutions holding 422 1,083 –
Change in shares held, QoQ +5.5% +0.3% –
Institutions buying 233 530 –
Institutions selling 138 424 –
Buyers to sellers 1.69 1.25 –

Return Correlation

Daily returns, last 12 months

1.00 means two stocks move in lockstep, 0 that they move independently. Pairs below about 0.5 diversify each other.

ICLRIQVNTRB
ICLR 1.00 0.55 0.15
IQV 0.55 1.00 0.16
NTRB 0.15 0.16 1.00

Add a Peer

Largest companies in the same industry

Related Comparisons

Frequently Asked Questions

Which is bigger, ICLR, IQV and NTRB?

Iqvia Holdings (IQV) is the largest by market capitalisation: Icon (ICLR) $16.37B, Iqvia Holdings (IQV) $45.93B, NutriBand (NTRB) $77.80M.

Which stock is cheaper, ICLR, IQV and NTRB?

Iqvia Holdings (IQV) trades on the lowest price-to-earnings ratio (Icon (ICLR) 36.5x, Iqvia Holdings (IQV) 33.0x, NutriBand (NTRB) -11.2x). On next year's consensus earnings, NutriBand (NTRB) is cheapest (Icon (ICLR) 17.9x, Iqvia Holdings (IQV) 22.4x, NutriBand (NTRB) 3.6x). A lower multiple can reflect slower expected growth, so read it next to the growth figures.

Which company is growing faster?

Iqvia Holdings (IQV) grew revenue fastest over the trailing twelve months: Icon (ICLR) +1.8%, Iqvia Holdings (IQV) +8.8%, NutriBand (NTRB) -37.3%.

Which company is more profitable?

Iqvia Holdings (IQV) has the highest net margin (Icon (ICLR) 5.4%, Iqvia Holdings (IQV) 8.1%, NutriBand (NTRB) -430.4%). On return on invested capital, Iqvia Holdings (IQV) leads (Icon (ICLR) 4.7%, Iqvia Holdings (IQV) 8.2%).

Which stock has performed better?

Over the past year Iqvia Holdings (IQV) returned the most: Icon (ICLR) +0.5%, Iqvia Holdings (IQV) +25.0%, NutriBand (NTRB) -15.4%. Over five years, NutriBand (NTRB) compounded fastest (Icon (ICLR) -8.6%/yr, Iqvia Holdings (IQV) +1.1%/yr, NutriBand (NTRB) +2.7%/yr). Returns are price only, before dividends.

Which stock is riskier?

By one-year price volatility, Iqvia Holdings (IQV) has been the steadiest (Icon (ICLR) 73.7%, Iqvia Holdings (IQV) 40.3%, NutriBand (NTRB) 80.0%). Volatility measures how widely the price swings, not the risk of the business.

Which is the better stock, ICLR, IQV and NTRB?

There is no single answer; it depends on what you are buying for. On the 12 head-to-head measures on this page, Iqvia Holdings (IQV) leads on 7. Business Quant does not give investment advice; use the comparison as a starting point for your own research.

Data from SEC filings, exchange prices and consensus estimates, via Business Quant. Percentile scores compare each company with its own peer group, so two companies' scores are each relative to different peers unless you rank against the whole market. Price returns exclude dividends. Nothing on this page is investment advice.